Literature DB >> 11510804

The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma.

O M Kon1, B S Sihra, L C Loh, J Barkans, C H Compton, N C Barnes, M Larché, A B Kay.   

Abstract

CD4+ T-cells are likely to be involved as a source of pro-inflammatory cytokines in asthma. This study assessed the effects of an infusion of keliximab (IDEC CE9.1), an anti-CD4+ monoclonal antibody, on peripheral blood CD4+ T-cells in corticosteroid-dependent asthmatics. Three cohorts of patients (termed C0.5: n=6, C1.5: n=5, and C3.0: n=5) received a single infusion of 0.5, 1.5 or 3.0 mg x kg(-1), respectively, with a fourth receiving placebo (Cpl: n=6), and were followed-up for 4 weeks. By flow cytometry in peripheral blood, pre- and postinfusion assessment was made of: a) CD4 and CD8 counts and mean fluorescence; b) CD25, human leukocyte antigen-DR (HLA-DR), CD45RO and CD45RA expression on CD4+ T-cells; and c) interferon (IFN)-gamma, interleukin (IL)-4 and IL-5 expression in CD4+ T-cells. Keliximab's in vitro effects on allergen-specific peripheral blood mononuclear cells (PBMC) proliferation in atopic asthmatics were also evaluated. There was a significant increase in lung function (peak expiratory flow rate) in the C3.0 group. Following infusion in C0.5, C1.5 and C3.0 but not Cpl: 1) the CD4, but not CD8 count was significantly decreased; 2) there was total loss of Leu3a staining; 3) there were significant reductions in the mean fluorescence of OKT4 binding; and 4) there were significant reductions in the numbers of CD25, HLA-DR, CD45RO and CD45RA/CD4+ cells. There were no changes in CD4+ cell expression of IFN-gamma, IL-4 or IL-5. Keliximab caused a significant reduction in T-cell proliferation as compared to a control monoclonal antibody. Keliximab, as an anti-CD4 monoclonal antibody, leads to a transient reduction in the number of CD4+ T-cells and modulation of CD4+ receptor expression in severe asthmatics. The effects of keliximab may be mediated through a decrease in CD4+ surface expression and T-lymphocyte numbers, in addition to a reduction in allergen-induced proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11510804     DOI: 10.1183/09031936.01.00064101

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

Review 1.  Glucocorticoid-resistant asthma.

Authors:  Tuck-Kay Loke; Ana R Sousa; Christopher J Corrigan; Tak H Lee
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 2.  Janus kinase-3 dependent inflammatory responses in allergic asthma.

Authors:  Rama Malaviya; Debra L Laskin; Ravi Malaviya
Journal:  Int Immunopharmacol       Date:  2010-04-27       Impact factor: 4.932

Review 3.  The future of asthma therapy: integrating clinical and experimental studies.

Authors:  David B Corry; Farrah Kheradmand
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 4.  Innate and adaptive immune responses in asthma.

Authors:  Stephen T Holgate
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 5.  Airway smooth muscle in the pathophysiology and treatment of asthma.

Authors:  Diana C Doeing; Julian Solway
Journal:  J Appl Physiol (1985)       Date:  2013-01-10

Review 6.  Monoclonal antibodies for the treatment of severe asthma.

Authors:  Salvatore Clienti; Jaymin B Morjaria; Elisa Basile; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 7.  Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.

Authors:  Michelle Fox Huffaker; Wanda Phipatanakul
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

Review 8.  Monoclonal antibodies and other biologic agents in the treatment of asthma.

Authors:  Aidan A Long
Journal:  MAbs       Date:  2009-05-04       Impact factor: 5.857

9.  CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients.

Authors:  Seamus Grundy; Manminder Kaur; Jonathan Plumb; Sophie Reynolds; Simon Hall; David House; Malcolm Begg; David Ray; Dave Singh
Journal:  Clin Sci (Lond)       Date:  2014-02       Impact factor: 6.124

Review 10.  Stratified approaches to the treatment of asthma.

Authors:  Stephen T Holgate
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.